Literature DB >> 27091190

Acquired ALK L1152R Mutation Confers Resistance to Ceritinib and Predicts Response to Alectinib.

Nishan Tchekmedyian1, Siraj M Ali2, Vincent A Miller2, Eric B Haura3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27091190     DOI： 10.1016/j.jtho.2016.03.018

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  11 in total

Review 1.  Canadian perspectives: update on inhibition of ALK-positive tumours in advanced non-small-cell lung cancer.

Authors:  B Melosky; P Cheema; J Agulnik; R Albadine; D G Bebb; N Blais; R Burkes; C Butts; P B Card; A M Y Chan; V Hirsh; D N Ionescu; R Juergens; W Morzycki; Z Poonja; R Sangha; M Tehfe; M S Tsao; M Vincent; Z Xu; G Liu
Journal:  Curr Oncol       Date:  2018-10-31       Impact factor: 3.677

2.  Transcriptomics-Guided Personalized Prescription of Targeted Therapeutics for Metastatic ALK-Positive Lung Cancer Case Following Recurrence on ALK Inhibitors.

Authors:  Elena Poddubskaya; Alexey Bondarenko; Alexander Boroda; Evgenia Zotova; Alex Glusker; Svetlana Sletina; Luidmila Makovskaia; Philipp Kopylov; Marina Sekacheva; Alexey Moisseev; Madina Baranova
Journal:  Front Oncol       Date:  2019-10-15       Impact factor: 6.244

Review 3.  Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib.

Authors:  Biagio Ricciuti; Andrea De Giglio; Carmen Mecca; Cataldo Arcuri; Sabrina Marini; Giulio Metro; Sara Baglivo; Angelo Sidoni; Guido Bellezza; Lucio Crinò; Rita Chiari
Journal:  Med Oncol       Date:  2018-04-17       Impact factor: 3.064

4.  The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.

Authors:  Jiaxiong Lu; Shan Guan; Yanling Zhao; Yang Yu; Sarah E Woodfield; Huiyuan Zhang; Kristine L Yang; Shayahati Bieerkehazhi; Lin Qi; Xiaonan Li; Jerry Gu; Xin Xu; Jingling Jin; Jodi A Muscal; Tianshu Yang; Guo-Tong Xu; Jianhua Yang
Journal:  Cancer Lett       Date:  2017-04-26       Impact factor: 8.679

Review 5.  Diagnosis and Treatment of Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer.

Authors:  Kathryn C Arbour; Gregory J Riely
Journal:  Hematol Oncol Clin North Am       Date:  2017-02       Impact factor: 3.722

6.  Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer.

Authors:  Caroline E McCoach; Anh T Le; Katherine Gowan; Kenneth Jones; Laura Schubert; Andrea Doak; Adriana Estrada-Bernal; Kurtis D Davies; Daniel T Merrick; Paul A Bunn; W Tom Purcell; Rafal Dziadziuszko; Marileila Varella-Garcia; Dara L Aisner; D Ross Camidge; Robert C Doebele
Journal:  Clin Cancer Res       Date:  2018-04-10       Impact factor: 12.531

Review 7.  Unveiling changes in the landscape of patient populations in cancer early drug development.

Authors:  Cinta Hierro; Analía Azaro; Guillem Argilés; Elena Elez; Patricia Gómez; Joan Carles; Jordi Rodon
Journal:  Oncotarget       Date:  2017-02-21

Review 8.  Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes.

Authors:  Geeta Geeta Sharma; Ines Mota; Luca Mologni; Enrico Patrucco; Carlo Gambacorti-Passerini; Roberto Chiarle
Journal:  Cancers (Basel)       Date:  2018-02-28       Impact factor: 6.639

Review 9.  Anaplastic lymphoma kinase inhibition in metastatic non-small cell lung cancer: clinical impact of alectinib.

Authors:  Ittai B Muller; Adrianus J de Langen; Elisa Giovannetti; Godefridus J Peters
Journal:  Onco Targets Ther       Date:  2017-09-13       Impact factor: 4.147

Review 10.  The activity, safety, and evolving role of brigatinib in patients with ALK-rearranged non-small cell lung cancers.

Authors:  Joshua K Sabari; Fernando C Santini; Alison M Schram; Isabella Bergagnini; Ruqin Chen; Chebli Mrad; W Victoria Lai; Kathryn C Arbour; Alexander Drilon
Journal:  Onco Targets Ther       Date:  2017-04-06       Impact factor: 4.147
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.